ArticleOncotarget2014

The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells.

Hisato Kawakami et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.